The review, titled “Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives,” describes the tumor microenvironment as an active biological network rather than a passive structure surrounding cancer cells. Glioma cells release cytokines, chemokines, growth factors and extracellular-matrix-modifying enzymes that reshape neighboring cells. In response, immune and stromal cells alter their behavior in ways that can benefit the tumor. The result is a paradoxical state sometimes described as “inflammation without immunity”: immune cells accumulate in the tumor, but many become functionally suppressed and incapable of mounting an effective antitumor response.

Resident microglia, the brain’s innate immune sentinels, are among the first cells to be reprogrammed. Glioma-derived molecules such as Versican can push microglia toward a pro-tumorigenic phenotype. Once polarized, these cells may support invasion through matrix metalloproteinase-14, or MMP14, and other mediators including stress-inducible protein 1, secreted phosphoprotein 1 and epidermal growth factor. They can also contribute to immune suppression by expressing programmed death-ligand 1, or PD-L1, and transforming growth factor beta. These signals weaken local T-cell activity while helping malignant cells move through the surrounding brain tissue.

Circulating monocytes provide another major source of tumor-associated macrophages. Gliomas recruit these cells through chemokine systems such as the CCL2/CCR2 and CSF1/CSF1R pathways. After entering the tumor, monocytes differentiate into macrophages with a broad functional spectrum. A minority may retain inflammatory properties and release interleukin-1 beta, interleukin-27 and tumor necrosis factor. However, the review emphasizes that most adopt an anti-inflammatory and immunosuppressive state marked by PD-L1, transforming growth factor beta, interleukin-10 and arginase 1. These macrophages also promote blood-vessel formation through vascular endothelial growth factor and epidermal growth factor, while MMP2 helps remodel the extracellular matrix and opens pathways for invasion.

Other myeloid populations further reinforce this immune barrier. Neutrophils can be drawn into the glioma microenvironment through interleukin-8 signaling, where they may encourage additional recruitment of neutrophils and monocytes. Their expression of arginase 1 can deprive T cells of essential metabolic resources and restrict their ability to proliferate. Yet the review highlights an important exception: hybrid dendritic-like neutrophils may possess antitumor properties by presenting signals that prime T-cell cytotoxicity and support immune memory. Myeloid-derived suppressor cells, or MDSCs, are recruited through CCL2 and stromal cell-derived factor 1 alpha, also known as SDF-1α. They suppress adaptive immunity using arginase 1, inducible nitric oxide synthase, PD-L1 and transforming growth factor beta.

Dendritic cells, which normally function as professional antigen-presenting cells, are also undermined by the glioma environment. Tumor-derived vascular endothelial growth factor, interleukin-6 and interleukin-10 can interfere with dendritic-cell maturation and reduce their capacity to process and present tumor antigens. Without effective antigen presentation, T cells are not properly activated against malignant cells. Even when T cells do enter the tumor, they frequently encounter an environment dominated by inhibitory signals. Repeated engagement between PD-1 on T cells and PD-L1 on tumor or immune cells can drive exhaustion or apoptosis, while transforming growth factor beta and indoleamine 2,3-dioxygenase 1 further suppress T-cell metabolism and function. This helps explain why immune infiltration does not necessarily translate into tumor control.

The neural nature of the brain adds another layer of complexity. Research summarized in the review shows that glioma cells can form functional excitatory synapses with neurons. Through these connections, neuronal activity and neurotransmitters such as glutamate can directly stimulate tumor-cell signaling and growth. Glioma cells may also exploit gamma-aminobutyric acid and neurotrophic factors, including neuroligin-3, brain-derived neurotrophic factor, insulin-like growth factor 1 and semaphorin 4F. Neuroligin-3 is particularly important because neuronal activity can trigger its release, activating growth programs in glioma cells. This creates a feed-forward loop in which active neural circuits promote tumor expansion, while the expanding tumor becomes increasingly integrated into the surrounding brain network.

Astrocytes and oligodendrocyte-lineage cells are similarly drawn into the tumor-supporting system. Reactive astrocytes can communicate with glioma cells through gap junctions, allowing direct exchange of ions and signaling molecules. Additional interactions involving interleukin-11 and its receptor, as well as annexin A1-related signaling, may promote invasion and suppress T-cell immunity. Although the review gives less emphasis to oligodendrocyte-lineage cells, it identifies them as additional participants in glioma progression, with potential roles in angiogenesis and immune escape. Together, these findings challenge the traditional view that the malignant cell is the only biologically relevant target inside the brain.

The vascular system provides both nutrients and a route for tumor dissemination. Glioma-associated endothelial cells respond to vascular endothelial growth factor and fibroblast growth factor, driving the formation of abnormal blood vessels. These vessels are often tortuous, structurally fragile and poorly organized. Their dysfunction disrupts the blood-brain barrier, increasing the movement of peripheral immune cells into the tumor while simultaneously creating profound therapeutic obstacles. Abnormal perfusion can produce regions of hypoxia and impaired drug distribution, meaning that a medicine may reach some tumor compartments but fail to penetrate others. Lymphatic endothelial cells may also participate directly in tumor progression through the CCL21/CCR7 signaling axis, adding another route of communication between glioma cells and the surrounding tissue.

The review argues that these interconnected mechanisms demand a broader therapeutic strategy. Blocking tumor-cell proliferation alone may not be enough if microglia and macrophages remain immunosuppressive, neuronal activity continues to stimulate growth, and abnormal vessels prevent adequate drug delivery. Potential approaches include reprogramming tumor-associated macrophages, inhibiting monocyte recruitment through the CCL2/CCR2 or CSF1/CSF1R axes, targeting MDSCs, restoring dendritic-cell function and combining immune checkpoint blockade with methods that reverse T-cell exhaustion. Interfering with neuron-glioma synapses, neuroligin-3 signaling, glutamatergic stimulation or astrocyte-mediated communication could provide additional ways to disrupt the tumor’s neural support system. The authors present the glioma microenvironment not only as the central engine of therapeutic resistance but also as a source of new vulnerabilities. By dismantling the ecosystem that protects malignant cells, future treatments may move beyond attacking the tumor in isolation and instead disable the biological network that allows it to survive.

Subject of Research: Glioma tumor microenvironment and cellular crosstalk

Article Title: Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives

News Publication Date: 15 June 2026

Web References: https://doi.org/10.1097/CM9.0000000000004151

References: Zhao L. “Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives.” Chinese Medical Journal. DOI: 10.1097/CM9.0000000000004151

Image Credits: Chinese Medical Journal

Keywords: glioma, brain cancer, tumor microenvironment, neuro-oncology, microglia, macrophages, immunosuppression, T-cell exhaustion, glioma immunotherapy, neuron-tumor communication, astrocytes, tumor-associated macrophages, blood-brain barrier, cancer neuroscience

Gliomas, malignant tumors arising from glial cells in the brain, remain notoriously challenging to study due to their heterogeneity and complex interactions with the brain microenvironment. Traditional two-dimensional models and animal studies have long been limited in their capacity to accurately recapitulate the cellular diversity and three-dimensional architecture intrinsic to human gliomas. This limitation has hindered translational efforts to develop effective therapies. The advent of organoid technology—three-dimensional, human-cell derived tissue cultures—provides an unprecedented opportunity for modeling glioma biology with enhanced fidelity to human disease.

The review article, entitled “Modeling Gliomas with Organoids: Classification, Fidelity, and Guidelines for Translational Neuro-Oncology,” meticulously dissects various approaches to generating glioma organoids. These include engineered organoids built from defined cellular components, patient tissue-derived organoids that retain the native tumor heterogeneity, and assembloids—a novel approach combining multiple organoids to simulate tumor-microenvironment interactions. This layered analysis highlights the strengths and limitations inherent to each model system and underscores the necessity for standardized terminology and classification to bridge gaps in reproducibility and comparability.

Central to the review is the proposal of a three-tier taxonomy for glioma organoid models, designed to refine how researchers categorize and apply these systems. This classification hinges on criteria such as the origin of the cells used, the extent to which the three-dimensional architecture mimics native tissue, and the degree to which critical features like microenvironmental interactions and genetic heterogeneity are recapitulated. By providing a common language and framework, the review encourages a cohesive research ecosystem that facilitates collaboration, data sharing, and comparative analyses.

Beyond classification, the review sets forth evidence-based guidelines to aid investigators in selecting the most appropriate glioma organoid model aligned with specific translational objectives. These guidelines consider factors such as scalability for high-throughput drug screening, fidelity in preserving in vivo tumor characteristics, and capacity for vascularization—critical for mimicking tumor blood supply and therapeutic responses. In doing so, the authors delineate a roadmap that addresses current technological bottlenecks, including challenges in expanding organoids while maintaining cellular complexity and viability.

Research co-leader Zhaohui Wang highlights the timeliness of this work, emphasizing the field’s dynamic yet fragmented nature. “Glioma organoid science is advancing at an astonishing pace, but inconsistent methodologies and terminology have created barriers to collaborative progress,” Wang explains. “Our review aims to unify the community around a structured, shared framework that will catalyze more robust and translationally relevant research.”

The implications of this review extend well beyond academic boundaries. Acting Director of the Terasaki Institute, Dr. Xiling Shen, accentuates the clinical significance, noting that “by harmonizing the standards and accelerating translational applications of glioma organoids, this work serves as a vital link between laboratory innovation and patient-centered therapeutic breakthroughs.”

The intrinsic complexity of gliomas—characterized by cellular heterogeneity, invasive growth patterns, and treatment resistance—necessitates models that truly reflect the intricacies of human pathology. Organoid technology uniquely provides a multidimensional platform where researchers can probe the biology of gliomas in a human-relevant context. This includes the preservation of cell populations such as glioma stem cells, critical players in tumor propagation and resistance, and the replication of tumor niches.

Historically, preclinical models have fallen short by failing to embody tumor microenvironments or genetic diversity, which are pivotal for therapeutic responses. Glioma organoids, with their architecture and cellular heterogeneity preserved, allow researchers to dissect mechanisms of tumor progression and drug resistance with unprecedented accuracy. This positions organoid platforms as transformative tools for predicting patient-specific responses, thus enhancing personalized medicine strategies.

Furthermore, the introduction of assembloids—integrative constructs combining glioma organoids with other brain tissues, such as vasculature or immune components—addresses critical interactions between tumor and microenvironmental elements. This holistic modeling offers opportunities to decode tumor biology within physiologically relevant contexts, enabling investigations into immune evasion, angiogenesis, and metastasis mechanisms at a molecular level.

The review also courageously tackles ongoing challenges in the glioma organoid field, such as scalability hurdles that impede widespread adoption in drug development pipelines. Maintaining organoid viability while achieving vascularization remains another frontier. Strategies involving microfluidics, engineered biomaterials, and co-culture systems are outlined by the authors as promising avenues to elevate organoid complexity and experimental relevance.

Notably, the consortium behind this review includes a diverse array of experts from premier institutions like the University of Pennsylvania, Case Western Reserve University, UCLA, and Emory University, reflecting a truly collaborative spirit aimed at transforming neuro-oncology research paradigms. Emerging scientists included in this collective effort signal a sustained commitment to nurturing innovative research across the glioma organoid landscape.

In sum, this seminal review not only crystallizes the current status of glioma organoid models but also forges a visionary path forward, equipping researchers with the tools and frameworks necessary to harness these technologies for robust translational applications. As gliomas continue to claim countless lives worldwide, this unified approach promises to accelerate the discovery of effective, lifesaving therapies that are urgently needed.

For inquiries and further information, contact Dr. Zhaohui Wang at the Terasaki Institute for Biomedical Innovation via email at zhaohui.wang@terasaki.org.

Subject of Research: Not applicable

Article Title: Modeling gliomas with organoids: Classification, fidelity, and guidelines for translational neuro-oncology

News Publication Date: June 15, 2026

Web References: http://dx.doi.org/10.1093/neuonc/noag085

Image Credits: Terasaki Institute for Biomedical Innovation

Keywords

Cancer, Neuroscience, Biotechnology, Stem cells, Drug discovery